These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12019190)

  • 1. Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding.
    Tang C; Lin Y; Rodrigues AD; Lin JH
    Drug Metab Dispos; 2002 Jun; 30(6):648-54. PubMed ID: 12019190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation.
    Ludden LK; Ludden TM; Collins JM; Pentikis HS; Strong JM
    J Pharmacol Exp Ther; 1997 Jul; 282(1):391-6. PubMed ID: 9223579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.
    Doecke CJ; Veronese ME; Pond SM; Miners JO; Birkett DJ; Sansom LN; McManus ME
    Br J Clin Pharmacol; 1991 Feb; 31(2):125-30. PubMed ID: 2049228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9.
    Rowland A; Elliot DJ; Knights KM; Mackenzie PI; Miners JO
    Drug Metab Dispos; 2008 May; 36(5):870-7. PubMed ID: 18256202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes.
    Wang JS; Wen X; Backman JT; Neuvonen PJ
    J Pharmacol Exp Ther; 2002 Jul; 302(1):43-9. PubMed ID: 12065698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes.
    Zhou Q; Matsumoto S; Ding LR; Fischer NE; Inaba T
    Life Sci; 2004 Sep; 75(18):2145-55. PubMed ID: 15325841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9.
    Veronese ME; Mackenzie PI; Doecke CJ; McManus ME; Miners JO; Birkett DJ
    Biochem Biophys Res Commun; 1991 Mar; 175(3):1112-8. PubMed ID: 2025243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity.
    Tang C; Shou M; Rodrigues AD
    Drug Metab Dispos; 2000 May; 28(5):567-72. PubMed ID: 10772636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.
    Carlile DJ; Hakooz N; Bayliss MK; Houston JB
    Br J Clin Pharmacol; 1999 Jun; 47(6):625-35. PubMed ID: 10383540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenytoin-Bovine Serum Albumin interactions - modeling plasma protein - drug binding: A multi-spectroscopy and in silico-based correlation.
    Suresh PK; Divya N; Nidhi S; Rajasekaran R
    Spectrochim Acta A Mol Biomol Spectrosc; 2018 Mar; 193():523-527. PubMed ID: 29304487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenytoin metabolism to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH) in man, cat and rat in vitro and in vivo, and susceptibility to phenytoin-induced gingival overgrowth.
    Kamali F; Ball DE; McLaughlin WS; Seymour RA
    J Periodontal Res; 1999 Apr; 34(3):145-53. PubMed ID: 10384402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P450 2C18 catalyzes the metabolic bioactivation of phenytoin.
    Kinobe RT; Parkinson OT; Mitchell DJ; Gillam EM
    Chem Res Toxicol; 2005 Dec; 18(12):1868-75. PubMed ID: 16359177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data.
    Ashforth EI; Carlile DJ; Chenery R; Houston JB
    J Pharmacol Exp Ther; 1995 Aug; 274(2):761-6. PubMed ID: 7636740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxorubicin alters the disposition of phenytoin by reducing its metabolic elimination and binding affinity to serum albumin in rats.
    Fukuno S; Nagai K; Yamaoka S; Yamada F; Mizumoto H; Ito T; Konishi H
    J Pharm Pharmacol; 2022 Feb; 74(2):200-207. PubMed ID: 34923583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters.
    Rowland A; Knights KM; Mackenzie PI; Miners JO
    Drug Metab Dispos; 2009 Jul; 37(7):1395-403. PubMed ID: 19398502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination.
    Brown HS; Chadwick A; Houston JB
    Drug Metab Dispos; 2007 Nov; 35(11):2119-26. PubMed ID: 17724064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible function of astrocyte cytochrome P450 in control of xenobiotic phenytoin in the brain: in vitro studies on murine astrocyte primary cultures.
    Meyer RP; Knoth R; Schiltz E; Volk B
    Exp Neurol; 2001 Feb; 167(2):376-84. PubMed ID: 11161626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P-450 2C9-reconstituted system.
    Palamanda J; Feng WW; Lin CC; Nomeir AA
    Drug Metab Dispos; 2000 Jan; 28(1):38-43. PubMed ID: 10611138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily.
    Veronese ME; Doecke CJ; Mackenzie PI; McManus ME; Miners JO; Rees DL; Gasser R; Meyer UA; Birkett DJ
    Biochem J; 1993 Jan; 289 ( Pt 2)(Pt 2):533-8. PubMed ID: 8424795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner.
    Liu KH; Kim MJ; Jung WM; Kang W; Cha IJ; Shin JG
    Drug Metab Dispos; 2005 Feb; 33(2):209-13. PubMed ID: 15537834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.